Pancreatic cancer is highly resistant to chemotherapy that is largely associated with constitutive activation of NF-κB (Long et al., 2011), and cisplatin is known to induce drug resistance in carcinoma cell lines via regulating NF-κB pathway (Chuang et al., 2002; Yeh et al., 2002; Yeh et al., 2003; Li et al., 2005). This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.